The final 2020 Dyslipidemia CPG was submitted to the EBPWG in April 2020. Appendix B: Cardiovascular Disease Risk Calculators Table B-1. Risk Calculators: Characteristics of Patient Population ACC/AHA pooled cohort PCE SRSRF VARS-CVD Framingham Sex Race Black/African American Age Abbreviations: ACA/AHA: American College of Cardiology/American Heart Association; PCE: Pooled Cohort Equations; SRSRF: Self- Reported Stroke Risk Function; VARS-CVD: Veterans Affairs Risk Score for Cardiovascular Disease Appendix C: Pharmacotherapy Table C-1. Summary of Statin and Non-statin Pharmacologic Agents* Drug Category Dose Major Drug Interactions Adverse Drug Reactions Notes Statins Atorvastatin once daily Since statins vary in their metabolic pathway, refer to product labeling for drug-drug interactions and statin dose limits Risk for myalgia, myopathy and, very rarely, rhabdomyolysis. Other risks include diabetes, LFT elevations, and asymptomatic CK elevations. First line therapy for primary or secondary prevention of CVD Rosuvastatin 5 40 mg once daily Simvastatin 5 40 mg once daily Lovastatin once daily Pravastatin once daily Fluvastatin 20 80 mg per day Pitavastatin 1 4 mg once daily Cholesterol absorption inhibitors Ezetimibe 10 mg once daily Increased incidence of transaminase elevation >3x ULN when combined with statins versus statins respectively) Generally well tolerated Benefit for reducing non- fatal CV events in secondary prevention patients in addition to statin inhibitors Alirocumab 75 mg once every 2 weeks OR 300 mg once every 4 weeks Max: 150 mg every 2 weeks No known significant interactions Injection site reactions (3 7%). Adverse reactions inhibitors reported in RCTs appear to be similar to placebo. 